Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [21] Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
    Khoo, Chin Meng
    Deerochanawong, Chaicharn
    Chan, Siew Pheng
    Matawaran, Bien
    Sheu, Wayne Huey-Herng
    Chan, Juliana
    Mithal, Ambrish
    Luk, Andrea
    Suastika, Ketut
    Yoon, Kun-Ho
    Ji, Linong
    Man, Nguyen Huu
    Pollock, Carol
    DIABETES OBESITY & METABOLISM, 2021, 23 (02) : 299 - 317
  • [22] Chronic kidney disease in patients with type 2 diabetes mellitus
    Kujawa-Szewieczek, Agata
    Piecha, Grzegorz
    Wiecek, Andrzej
    CLINICAL DIABETOLOGY, 2012, 1 (06): : 223 - 232
  • [23] Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
    DeFronzo, Ralph A.
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1197 - 1205
  • [24] Predictors of chronic kidney disease in type 2 diabetes A longitudinal study from the AMD Annals initiative
    De Cosmo, Salvatore
    Viazzi, Francesca
    Pacilli, Antonio
    Giorda, Carlo
    Ceriello, Antonio
    Gentile, Sandro
    Russo, Giuseppina
    Rossi, Maria C.
    Nicolucci, Antonio
    Guide, Pietro
    Pontremoli, Roberto
    MEDICINE, 2016, 95 (27)
  • [25] Best Practices in the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
    Shubrook, Jay H.
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Manley, Tom
    Tuttle, Katherine R.
    DIABETOLOGY, 2023, 4 (04): : 453 - 464
  • [26] Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
    Edmonston, Daniel
    Lydon, Elizabeth
    Mulder, Hillary
    Chiswell, Karen
    Lampron, Zachary
    Marsolo, Keith
    Goss, Ashley
    Ayoub, Isabelle
    Shah, Raj C.
    Chang, Alexander R.
    Ford, Daniel E.
    Jones, W. Schuyler
    Fonesca, Vivian
    Machineni, Sriram
    Fort, Daniel
    Butler, Javed
    Hunt, Kelly J.
    Pitlosh, Max
    Rao, Ajaykumar
    Ahmad, Faraz S.
    Gordon, Howard S.
    Hung, Adriana M.
    Hwang, Wenke
    Bosworth, Hayden B.
    Pagidipati, Neha J.
    JAMA NETWORK OPEN, 2024, 7 (06) : e2418808
  • [27] Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications
    Abu-Alfa, Ali K.
    Atallah, Paola J.
    Azar, Sami T.
    Dagher, Elissar C.
    Echtay, Akram S.
    El-Amm, Mireille A.
    Hazkial, Habib G.
    Kassab, Roland Y.
    Medlej, Rita C.
    Mohamad, Malek A.
    DIABETES THERAPY, 2023, 14 (01) : 11 - 28
  • [28] Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Amod, Aslam
    Marre, Michel
    Joseph, Amer
    Lage, Andrea
    Scott, Charlie
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01) : 125 - 134
  • [29] External validation of prognostic models for chronic kidney disease among type 2 diabetes
    Saputro, Sigit Ari
    Pattanateepapon, Anuchate
    Pattanaprateep, Oraluck
    Aekplakorn, Wichai
    McKay, Gareth J.
    Attia, John
    Thakkinstian, Ammarin
    JOURNAL OF NEPHROLOGY, 2022, 35 (06) : 1637 - 1653
  • [30] Management of diabetes mellitus in chronic kidney disease
    Garla, Vishnu
    Kanduri, Swetha
    Yanes-Cardozo, Licy
    Lien, Lillian F.
    MINERVA ENDOCRINOLOGICA, 2019, 44 (03) : 273 - 287